#ASCO21: Novartis flashes 'groundbreaking data' for $2B radioligand drug
Here’s the “groundbreaking” data from the prostate cancer drug Novartis spent $2 billion to acquire: The molecule hit every endpoint in the Phase III trial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
